Unraveling the Mechanisms of Cardiovascular Aging: From Molecular Drivers to Therapeutic Strategies
Key Insights
A comprehensive review systematically examines the molecular, cellular, and physiological mechanisms linking aging to cardiovascular pathology, including metabolic dysregulation, mitochondrial dysfunction, chronic inflammation, and cellular senescence.
Key aging hallmarks such as genomic instability, epigenetic alterations, and deregulated nutrient-sensing pathways (mTOR (search), IGF-1 (search), AMPK (search)) are identified as core drivers of age-related cardiovascular diseases (search) including heart failure (search), atherosclerosis (search), and atrial fibrillation (search).
Current therapeutic strategies reviewed include lifestyle modifications, pharmacotherapy, gerotherapeutic interventions, and device-based management, alongside future directions in precision medicine and AI-powered strategies.
Aging is an inevitable biological process marked by progressive functional decline and elevated risk of cardiovascular diseases (search) (CVDs), and a newly published review in Cardiovascular Innovations and Applications systematically examines the clinical mechanisms linking aging to cardiovascular pathology.
The review focuses on the molecular, cellular, and physiological changes that contribute to cardiovascular aging, which in turn increases the incidence of heart failure (search), atherosclerosis (search), atrial fibrillation (search), and other diseases. Key mechanisms identified include metabolic dysregulation, mitochondrial dysfunction, chronic inflammation, cellular senescence, immune disorders, and epigenetic changes.
The Hallmarks Driving Cardiovascular Aging
The aging process is driven by a complex interplay of interconnected hallmarks. Primary hallmarks — including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, and disabled macroautophagy — represent the intrinsic mechanisms that directly cause cellular and molecular damage. Genomic instability, involving both nuclear DNA damage and mitochondrial DNA (mtDNA) mutations, is considered a core driver of aging. DNA damage activates inflammatory pathways such as NF-κB, releasing proinflammatory factors like IL-6 and TNF-α (search), and forms a multilevel positive feedback loop that drives aging by interfering with chromatin structure and altering epigenetic marks.
Epigenetic alterations, encompassing DNA methylation, histone modifications, and noncoding RNAs, play a significant role in regulating the aging phenotype. Several DNA methylation-based epigenetic clocks — including Horvath, Hannum, PhenoAge, and GrimAge — have demonstrated the ability to predict chronological age and offer valuable insights into organismal aging. Histone acetylation changes are also critical, with sirtuins such as SIRT1 (search) functioning as longevity proteins that modulate delayed premature aging.
Nutrient-Sensing Pathways and Mitochondrial Dysfunction
Three key nutrient-sensing pathways — mTOR (search), IGF-1 (search), and AMPK (search) — are central to aging regulation. Inhibition of the mTOR pathway has been shown to prolong lifespan across all species studied to date, while the responsiveness of AMPK activation decreases during aging. The interplay between these pathways is complex: long-term activation of IGF-1 and mTOR can inhibit the AMPK pathway, and maintaining the dynamic balance among IIS, mTOR, and AMPK activity remains a significant challenge.
Mitochondrial dysfunction represents another critical driver of cardiovascular aging. Mitochondrial quality control (MQC) coordinates protein homeostasis, biogenesis, dynamics, and mitophagy to ensure cellular homeostasis. Preclinical evidence suggests that modulation of MQC can be used to treat cardiac aging and cardiovascular diseases (search). However, either excessive activation or inhibition of MQC can cause accumulation of oxidized proteins and induce mitochondrial dysfunction.
Cellular Senescence and Chronic Inflammation
Cellular senescence — characterized by irreversible proliferation arrest, the senescence-associated secretory phenotype (SASP), and upregulation of antiapoptotic pathways — contributes significantly to cardiovascular pathology. Senescent cells can aggravate cardiovascular diseases (search) and atherosclerosis (search). Notably, not all senescent cells are detrimental; some participate in physiological processes such as wound healing and tissue remodeling.
Chronic inflammation, termed "inflammaging," represents a low-grade, systemic chronic inflammatory state that progressively accompanies aging. IL-6 signaling can drive cellular senescence through activation of the cGAS-STING-NF-κB pathway, and in age-related cardiovascular disorders, IL-6 exacerbates mitochondrial dysfunction in vascular endothelial cells, accelerating atherosclerosis (search) progression via oxidative stress and lipid accumulation.
Therapeutic Strategies and Future Directions
Current therapeutic strategies reviewed include lifestyle modifications, pharmacotherapy, gerotherapeutic interventions, and device-based management. mTOR (search) inhibitors such as RTB101 have shown promise in phase 2b and phase III clinical studies for improving immune capacity in the elderly. Rapamycin, an mTOR inhibitor, significantly prolongs lifespan in mice, though long-term administration has notable side effects including skin and metabolic disorders.
Future directions emphasize precision medicine, development of novel therapeutic targets, multi-omics approaches, and AI-powered strategies against cardiovascular aging. The review underscores that understanding these interconnected mechanisms is crucial for developing targeted interventions to delay cardiovascular aging and alleviate CVD burden in older people.
The integration of multi-omics approaches to analyze spatiotemporal dynamics and the development of precise delivery systems for targeted interventions represent promising avenues for future research. As the population ages globally, translating these mechanistic insights into effective clinical strategies remains a pressing priority for cardiovascular medicine.